Koers OKYO Pharma Limited London S.E.
Aandelen
OKYO
GG00BMFG5F62
Farmaceutische producten
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 51,35 mln. 47,84 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -11 mln. -10,25 mln. | Nettowinst (verlies) 2025 * | -15 mln. -13,98 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-3,86
x | K/w-verhouding 2025 * |
-4,07
x | Werknemers | 8 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 42,63% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Gary Jacob
CEO | Chief Executive Officer | 77 | 07-01-21 |
Keeren Shah
DFI | Director of Finance/CFO | 47 | 01-08-20 |
William Clementi
COO | Chief Operating Officer | - | 01-09-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
John Brancaccio
BRD | Director/Board Member | 76 | 10-06-20 |
Willy Simon
BRD | Director/Board Member | 72 | 01-06-15 |
Gabriele Cerrone
CHM | Chairman | 52 | 07-01-21 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-3,65% | 87,06 mld. | |
+2,76% | 40,25 mld. | |
-17,49% | 31,09 mld. | |
+54,44% | 24,74 mld. | |
-13,13% | 15,91 mld. | |
-9,12% | 11,96 mld. | |
-15,45% | 11,92 mld. | |
-42,56% | 11,61 mld. | |
+4,87% | 8,73 mld. |